AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03841812
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% Sevoflurane continuously using during intre-operation.
Trial: NCT03841812
Drug: 2 mg/kg/h Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg/kg/h Propofol continuously infused during intre-operation
Trial: NCT00521170
Drug: Levocetirizine
RxNorm normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01830231
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
Trial: NCT01830231
Drug: Vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years.
Trial: NCT04865289
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Trial: NCT01720056
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01375881
Drug: darunavir/ritonavir plus background regimen
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
Trial: NCT04865289
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Trial: NCT04865289
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Trial: NCT02866175
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
Trial: NCT02866175
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75 mg once-daily
Trial: NCT02866175
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: prasugrel 5mg or 10 mg once-daily
Trial: NCT02866175
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor 90 mg twice-daily
Trial: NCT03987152
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily intake of Sirolimus during Challenge and Rechallenge phase
Trial: NCT01595009
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus was supplied as tablets of 5mg strength.
Trial: NCT03758365
Drug: Clobetasol Propionate 0.05% Lotion
RxNorm normalized name: CLOBETASOL PROPIONATE 0.05% LOTION
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT03758365
Drug: Betamethasone Dipropionate 0.05% Cream
RxNorm normalized name: BETAMETHASONE DIPROPIONATE 0.05% CREAM
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT03758365
Drug: Triamcinolone Acetonide 0.1% Cream
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 0.1% CREAM
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT03758365
Drug: Desonide 0.05% Cream
RxNorm normalized name: DESONIDE 0.05% CREAM
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT00812682
Drug: Symbicort
RxNorm normalized name: Symbicort
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02623829
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
Trial: NCT02623829
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml of normal saline will be administered
Trial: NCT00195299
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03459170
Drug: rimiducid
RxNorm normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered to eliminate BPX-501 cells in the event of GVHD
Trial: NCT04339101
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via infusion
Trial: NCT04339101
Drug: Itacitinib Adipate
RxNorm normalized name: Adipic Acid
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04339101
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03086993
Drug: Cisplatin and Gemcitabine
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous treatment with Cis/Gem until disease progression
Trial: NCT01606566
Drug: Amphinex induced PCI of bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
Trial: NCT00875979
Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Trial: NCT04339101
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04339101
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT00875979
Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Trial: NCT00780026
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus or infusion 80 to 110 mg/dl
Trial: NCT02701478
Drug: N2O exposure
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
Trial: NCT04669665
Drug: SLS-002
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
Trial: NCT00875979
Drug: Pertuzumab 420 mg
RxNorm normalized name: pertuzumab 420 MG in 14 ML Injection
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab was provided as a single-use formulation.
Trial: NCT00843531
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/day (oral)
Trial: NCT00216476
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-30 mg oral once daily for 104 weeks
Trial: NCT00216476
Drug: Risperidone Long Acting Injectable (LAI)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
Trial: NCT00216476
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
Trial: NCT02182102
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00762957
Drug: TAK-559 and metformin
RxNorm normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
Trial: NCT00762957
Drug: TAK-559 and metformin
RxNorm normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
Trial: NCT00762957
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
Trial: NCT00468286
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months.
Trial: NCT00816504
Drug: Galactose
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Trial: NCT00992069
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of 600 mg daily, taken in the evening
Trial: NCT02318121
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01689259
Drug: Cyclobenzaprine tablets
RxNorm normalized name: cyclobenzaprine Oral Tablet
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Trial: NCT03109990
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the experimental group will receive Dexmedetomidine during surgery.
Trial: NCT00901407
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
Trial: NCT03109990
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive saline but not Dexmedetomidine during surgery.
Trial: NCT02737306
Drug: PRO 140
RxNorm normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Trial: NCT02511236
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
Trial: NCT00901407
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Trial: NCT00007878
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01497483
Drug: Pravastatin and Cyclosporine
RxNorm normalized name: pravastatin and ezetimibe
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
Trial: NCT04550195
Drug: BMS-986337
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT04043845
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
Trial: NCT00343980
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 4 mg once or twice a day.
Trial: NCT00343980
Drug: glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 4 mg/day.
Trial: NCT00763529
Drug: Mometasone
RxNorm normalized name: Mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate cream 0.1% applied once daily
Trial: NCT00763529
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate cream 0.05% applied twice daily
Trial: NCT00667160
Drug: tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT01193608
Drug: AAB-003 (PF-05236812)
RxNorm normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mg/kg AAB-003, IV
Trial: NCT01193608
Drug: AAB-003 (PF-05236812)
RxNorm normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg/kg AAB-003, IV
Trial: NCT00667160
Drug: pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT01193608
Drug: AAB-003 (PF-05236812)
RxNorm normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/kg AAB-003, IV
Trial: NCT01193608
Drug: AAB-003 (PF-05236812)
RxNorm normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg/kg AAB-003, IV
Trial: NCT00576784
Drug: pioglitazone and glimepiride
RxNorm normalized name: Pioglitazone and Glimepiride Tablets
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
Trial: NCT04312750
Drug: Lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01952145
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
Trial: NCT01952145
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
Trial: NCT03719586
Drug: ZMapp
RxNorm normalized name: Zmapp component c4g7
DrugBank: Larcaviximab (DB17775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
Trial: NCT03719586
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
Trial: NCT03719586
Drug: REGN-EB3
RxNorm normalized name: REGN-COV2
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Trial: NCT01193608
Drug: AAB-003 (PF-05236812)
RxNorm normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg/kg AAB-003, IV
Trial: NCT01784042
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02310477
Drug: regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: regorafenib for all groups
Trial: NCT01816477
Drug: Epidural (ropivicaine 0.25%)
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
Trial: NCT00001688
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001688
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001688
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00819247
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given as a subcutaneous injection.
Trial: NCT02476526
Drug: Low Volume iso-osmolar non-ionic radio contrast medium
RxNorm normalized name: iso-sulfan blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
Trial: NCT02476526
Drug: Sodium Bicarbonate Solution
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
Trial: NCT00924079
Drug: nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dosage form, 66 mg, single dose
Trial: NCT03120234
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03120234
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04708795
Drug: AP701
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Preparation of Cannabis flowers (Cannabis flos)
Trial: NCT03915938
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
Trial: NCT02462538
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
Trial: NCT02462538
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
Trial: NCT03467334
Drug: Simethicone 20 MG
RxNorm normalized name: simethicone 20 MG
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for infant colic